Strategic Partnerships Iktos has a history of high-value collaborations with pharma companies and now formalizes large-scale potential through Servier integration and Pierre Fabre collaboration, presenting a clear path for co-development and milestone-based sales deals.

Integrated AI and Robotics With the combined Makya and Spaya platforms plus Iktos Robotics, there is a compelling value proposition for end-to-end drug discovery acceleration, enabling upsell to existing partners and expansion into new therapeutic areas.

Expansion through Acquisitions The Synsight acquisition enhances biology discovery capabilities for PPIs and RPI targets, creating cross-sell opportunities to clients seeking integrated chemistry and biology AI solutions.

Scale via Grants and Funding Recent EIC Accelerator grant demonstrates government-backed validation and potential for follow-on funding, signaling readiness to scale and propose joint ventures or funded pilots with large pharmaceutical customers.

Global Enterprise Outreach Strategic partnerships and multi-year agreements with major pharma players indicate a favorable market reception; prioritize enterprise-level outreach to secure multi-million and potentially billion-euro deals focused on AI-driven molecular design and synthesis automation.